Phase I and II clinical trials for gastric cancer

Surgical Oncology Clinics of North America

Volumn 21, Issue 1, 2012, Pages 113-128

  Khushalani, Nikhil I ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Gastric cancer; Targeted agents

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; PAZOPANIB; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TIVANTINIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VORINOSTAT;

ACNE; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANOREXIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FATIGUE; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; METASTASIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOMA; STOMATITIS; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; VEIN THROMBOSIS; VOMITING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 82955180344     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2011.09.006     Document Type: Review

References (99)

1. Bertuccio P., Chatenoud L., Levi F., et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009, 125(3):666-673.
2. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
3. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
4. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345(10):725-730.
5. Macdonald JS, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). ASCO Meeting Abstracts. Orlando (FL), June 8, 2009;27(15S):4515.
6. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20.
7. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357(18):1810-1820.
8. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24(18):2903-2909.
9. Rivera F., Vega-Villegas M.E., Lopez-Brea M.F. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007, 33(4):315-324.
10. Scartozzi M., Galizia E., Freddari F., et al. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 2004, 30(5):451-459.
11. Findlay M., Cunningham D., Norman A., et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994, 5(7):609-616.
12. Zaniboni A., Barni S., Labianca R., et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer 1995, 76(10):1694-1699.
13. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36-46.
14. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24(31):4991-4997.
15. Shah MA, Shibata S, Stoller RG, et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). ASCO Meeting Abstracts. Orlando (FL), June 14, 2010;28(Suppl 15):4014.
16. Ajani J.A., Baker J., Pisters P.W., et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002, 94(3):641-646.
17. Bouche O., Raoul J.L., Bonnetain F., et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004, 22(21):4319-4328.
18. Al-Batran S.E., Atmaca A., Hegewisch-Becker S., et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004, 22(4):658-663.
19. De Vita F., Orditura M., Matano E., et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005, 92(9):1644-1649.
20. Jatoi A., Murphy B.R., Foster N.R., et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006, 17(1):29-34.
21. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
22. Owens J. Determining druggability. Nat Rev Drug Discov 2007, 6(3):187.
23. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82(1):4-6.
24. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl 1):2-10.
25. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9(6):653-660.
26. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676.
27. Akagi M., Kawaguchi M., Liu W., et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer 2003, 88(5):796-802.
28. Maeda K., Chung Y.S., Ogawa Y., et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77(5):858-863.
29. Fondevila C., Metges J.P., Fuster J., et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004, 90(1):206-215.
30. Yao J.C., Wang L., Wei D., et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004, 10(12 Pt 1):4109-4117.
31. Vidal O., Metges J.P., Elizalde I., et al. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 2009, 96(12):1443-1451.
32. Juttner S., Wissmann C., Jons T., et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006, 24(2):228-240.
33. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II Study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24(33):5201-5206.
34. Enzinger PC, Ryan DP, Regan EM, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. ASCO Meeting Abstracts. Orlando (FL), August 18, 2008;26(Suppl 15):4552.
35. El-Rayes B.F., Zalupski M., Bekai-Saab T., et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010, 21(10):1999-2004.
36. Shah M.A., Jhawer M., Ilson D.H., et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011, 29(7):868-874.
37. Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, [Epub ahead of print].
38. Smyth EC, Enzinger PC, Li J, et al. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. ASCO Meeting Abstracts. Orlando (FL), June 9, 2011;29(Suppl 15):4056.
39. Okines AF, Langley R, Cafferty FH, et al. Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. ASCO Meeting Abstracts. Orlando (FL), June 14, 2010;28(suppl 15):4019.
40. Okines AF, Langley RE, Thompson LC, et al. Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma. ASCO Meeting Abstracts. Orlando (FL), June 9, 2011;29(Suppl 15):4092.
41. Prewett M., Huber J., Li Y., et al. Antivascular Endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999, 59(20):5209-5218.
42. Spratlin J.L., Cohen R.B., Eadens M., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010, 28(5):780-787.
43. Bang Y.J., Kang Y.K., Kang W.K., et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011, 29(6):1449-1458.
44. Moehler M., Mueller A., Hartmann J.T., et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011, 47(10):1511-1520.
45. Khushalani NI, Fetterly GJ, Iyer RV, et al. Phase I study of sunitinib with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) for advanced gastroesophageal cancers. ASCO Meeting Abstracts. Orlando (FL), June 14, 2010;28(Suppl 15):TPS201.
46. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4(12):937-947.
47. Beeram M., Patnaik A., Rowinsky E.K. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005, 23(27):6771-6790.
48. Yang S., Ngo V.C., Lew G.B., et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther 2009, 8(9):2537-2545.
49. Kim C., Lee J.L., Choi Y.H., et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2010, [Epub ahead of print].
50. Sun W., Powell M., O'Dwyer P.J., et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010, 28(18):2947-2951.
51. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19(56):6550-6565.
52. Tokunaga A., Onda M., Okuda T., et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995, 75(Suppl 6):1418-1425.
53. Dragovich T., McCoy S., Fenoglio-Preiser C.M., et al. Phase II Trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006, 24(30):4922-4927.
54. Takehana T., Kunitomo K., Suzuki S., et al. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003, 1(6):438-445.
55. Lieto E., Ferraraccio F., Orditura M., et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008, 15(1):69-79.
56. Ciardiello F., De Vita F., Orditura M., et al. Cetuximab in the treatment of colorectal cancer. Future Oncol Apr 2005, 1(2):173-181.
57. Okines A., Cunningham D., Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol Aug 2011, 8(8):492-503.
58. Chan J.A., Blaszkowsky L.S., Enzinger P.C., et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Annals of Oncology June 1, 2011, 22(6):1367-1373.
59. Gold P.J., Goldman B., Iqbal S., et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol Sep 2010, 5(9):1472-1476.
60. Liu X., Guo W.J., Zhang X.W., et al. Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan. Cancer Chemother Pharmacol Oct 2011, 68(4):871-878.
61. Pinto C., Di Fabio F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol Mar 2007, 18(3):510-517.
62. Pinto C., Di Fabio F., Barone C., et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009, 101(8):1261-1268.
63. Kim C., Lee J.L., Ryu M.H., et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011, 29(2):366-373.
64. Moehler M., Mueller A., Trarbach T., et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol Jun 2011, 22(6):1358-1366.
65. Rao S., Starling N., Cunningham D., et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008, 99(6):868-874.
66. Rao S., Starling N., Cunningham D., et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010, 21(11):2213-2219.
67. Okines A.F., Ashley S.E., Cunningham D., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010, 28(25):3945-3950.
68. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000, 19(53):6102-6114.
69. Allgayer H., Babic R., Gruetzner K.U., et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000, 18(11):2201-2209.
70. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19(9):1523-1529.
71. Tanner M., Hollmen M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16(2):273-278.
72. Fujimoto-Ouchi K., Sekiguchi F., Yasuno H., et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59(6):795-805.
73. Shah MA, Janjigian YY, Pauligk C, et al. Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: a U.S. and European international collaborative analysis. ASCO Meeting Abstracts. Chicago (IL), June 9, 2011;29(Suppl 15):4014.
74. Krop I.E., Beeram M., Modi S., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28(16):2698-2704.
75. Barok M., Tanner M., Koninki K., et al. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011, 306(2):171-179.
76. Iqbal S., Goldman B., Fenoglio-Preiser C.M., et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011, [Epub ahead of print].
77. LaBonte M.J., Manegold P.C., Wilson P.M., et al. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer 2009, 125(12):2957-2969.
78. Wainberg Z.A., Anghel A., Desai A.J., et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010, 16(5):1509-1519.
79. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4(5):335-348.
80. Lang S.A., Gaumann A., Koehl G.E., et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007, 120(8):1803-1810.
81. Xu D.Z., Geng Q.R., Tian Y., et al. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer 2010, 10:536.
82. Okamoto I., Doi T., Ohtsu A., et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010, 40(1):17-23.
83. Doi T., Muro K., Boku N., et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010, 28(11):1904-1910.
84. Lim T., Lee J., Lee D.J., et al. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 2011, 68(1):255-262.
85. Birchmeier C., Birchmeier W., Gherardi E., et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4(12):915-925.
86. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7(6):504-516.
87. Lee J.H., Han S.U., Cho H., et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19(43):4947-4953.
88. Smolen G.A., Sordella R., Muir B., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006, 103(7):2316-2321.
89. Janjigian Y.Y., Tang L.H., Coit D.G., et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 2011, 20(5):1021-1027.
90. Yap T.A., Olmos D., Brunetto A.T., et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011, 29(10):1271-1279.
91. Jhawer M, Kindler HL, Wainberg Z, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study. ASCO Meeting Abstracts. Orlando (FL), June 8, 2009;27(15S):4502.
92. Eder J.P., Shapiro G.I., Appleman L.J., et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010, 16(13):3507-3516.
93. Saito H., Tsujitani S., Oka S., et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999, 86(8):1455-1462.
94. Ammanamanchi S., Brattain M.G. Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J Biol Chem 2004, 279(31):32620-32625.
95. Fetterly GJ, Brady WE, LeVea CM, et al. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). ASCO Meeting Abstracts. Orlando (FL), June 8, 2009;27(15S):e15540.
96. Schwartz G.K., Ilson D., Saltz L., et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001, 19(7):1985-1992.
97. Schwartz G.K., O'Reilly E., Ilson D., et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002, 20(8):2157-2170.
98. Shah M.A., Khanin R., Tang L., et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011, 17(9):2693-2701.
99. Kang Y.K., Kang W.K., Shin D.B., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009, 20(4):666-673.